TAM
TVRD

Tiverton Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Tiverton Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-409
Closed -$183K – 521
2018
Q1 		$183K Sell
409
-1,228
-75% -$596K 0.01% 335
2017
Q4 		$721K Sell
1,637
-966
-37% -$440K 0.05% 207
2017
Q3 		$1.28M Sell
2,603
-326
-11% -$163K 0.07% 154
2017
Q2 		$1.62M Sell
2,929
-977
-25% -$620K 0.09% 158
2017
Q1 		$2.59M Hold
3,906
– – 0.13% 148
2016
Q4 		$1.31M Hold
3,906
– – 0.08% 169
2016
Q3 		$1.17M Sell
3,906
-12,301
-76% -$2.67M 0.09% 139
2016
Q2 		$57.5M Buy
16,207
+9,828
+154% +$2.14M 2.42% 5
2016
Q1 		$1.43M Sell
6,379
-565
-8% -$169K 0.05% 146
2015
Q4 		$4.21M Hold
6,944
– – 0.13% 116
2015
Q3 		$3.57M Sell
6,944
-5,884
-46% -$3.94M 0.08% 125
2015
Q2 		$5.61M Hold
12,828
– – 0.11% 129
2015
Q1 		$4.64M Buy
12,828
+697
+6% +$264K 0.09% 124
2014
Q4 		$4.36M Buy
12,131
+1,017
+9% +$328K 0.09% 119
2014
Q3 		$3.36M Buy
11,114
+4,170
+60% +$1.71M 0.08% 117
2014
Q2 		$4.25M Hold
6,944
– – 0.1% 111
2014
Q1 		$4.65M Buy
+6,944
New +$4.11M 0.1% 111

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Tiverton Asset Management's TVRD Position: Q2 2018 in Review

Tiverton Asset Management sold out of Tvardi Therapeutics (TVRD) in Q2 2018, closing a stake of 409 shares — an estimated $183K sold.

Tiverton Asset Management first reported a position in TVRD in Q1 2014 and held it in 17 quarters. The position peaked at $57.5M in Q2 2016. 130 funds tracked by Wall St. Rank hold TVRD as of Q2 2018.

  • Tiverton Asset Management reported no remaining Tvardi Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Tiverton Asset Management sold 409 Tvardi Therapeutics shares in Q2 2018, an estimated $183K.
  • Tiverton Asset Management first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 17 quarters.
  • Tiverton Asset Management's Tvardi Therapeutics position peaked at $57.5M in Q2 2016.
  • 130 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2018.

Based on Tiverton Asset Management's 13F filing for Q2 2018, filed 10 Aug 2018.